- Home
- CDTX
as 07-26-2024 4:00pm EST
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's REZZAYO (rezafungin for injection) is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Upcoming Earnings Alert:
Get ready for potential market movements as Cidara Therapeutics Inc. CDTX prepares to release earnings report on 01 Aug 2024.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 54.8M | IPO Year: | 2015 |
| Target Price: | $61.67 | AVG Volume (30 days): | 31.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.00 - $24.40 | Next Earning Date: | 08-01-2024 |
| Revenue: | $46,378,000 | Revenue Growth: | -44.42% |
| Revenue Growth (this year): | -58.9% | Revenue Growth (next year): | -58.45% |
Stock Insider Trading Activity of Cidara Therapeutics Inc. (CDTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Stein Jeffrey | CDTX | President & CEO | Jun 7 '24 | Buy | $13.21 | 8,000 | $105,680.00 | 24,580 | SEC Form 4 |
| Tari Leslie | CDTX | CHIEF SCIENTIFIC OFFICER | Mar 11 '24 | Sell | $0.67 | 21,029 | $14,085.22 | 258,681 | SEC Form 4 |
| Shah Preetam | CDTX | CFO & CBO | Mar 11 '24 | Sell | $0.67 | 18,931 | $12,679.98 | 227,210 | SEC Form 4 |
| Sandison Taylor | CDTX | Chief Medical Officer | Mar 11 '24 | Sell | $0.67 | 20,662 | $13,839.41 | 347,095 | SEC Form 4 |
| Ward Shane | CDTX | COO & CLO | Mar 11 '24 | Sell | $0.67 | 20,473 | $13,712.82 | 198,770 | SEC Form 4 |
Latest Cidara Therapeutics Inc. News
CDTX Breaking Stock News: Dive into CDTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
Associated Press Finance
2 months ago
Cidara Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
2 months ago
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
2 months ago
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
GlobeNewswire
3 months ago
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Pharmaceutical Technology
3 months ago
Cidara buys back rights to flu therapy from J&J for $85m
MT Newswires
3 months ago
Top Premarket Gainers
Compare CDTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDTX Cidara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.